Tamoxifen and the Risk of Ovarian Cancer in BRCA1 Mutation Carriers

OBJECTIVE: BRCA1 mutation carriers have a high rate of both breast and ovarian cancer. Tamoxifen is a selective estrogen receptor modulator (SERM), which is used for the treatment of primary breast cancer and for the prevention of contralateral breast cancer. Our objective is to assess if tamoxifen...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Vicus, Danielle, Rosen, Barry, Lubinski, Jan, Domchek, Susan, Kauff, Noah D., Lynch, Henry T., Isaacs, Claudine, Tung, Nadine, Sun, Ping, Narod, Steven A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2009
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3756313/
https://ncbi.nlm.nih.gov/pubmed/19577280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2009.06.012
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller